Please use this identifier to cite or link to this item:
Title: Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer
Authors: Rajnakova, A. 
Moochhala, S.
Goh, P.M.Y 
Ngoi, S.-S. 
Keywords: Cyclooxygenase
Gastric cancer
Nitric oxide
Issue Date: 30-Oct-2001
Citation: Rajnakova, A., Moochhala, S., Goh, P.M.Y, Ngoi, S.-S. (2001-10-30). Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Letters 172 (2) : 177-185. ScholarBank@NUS Repository.
Abstract: The present study evaluated the significance of nitric oxide synthase (NOS), cyclooxygenase (COX) expression and p53 status in 55 patients with gastric adenocarcinoma and relationship of these molecular markers to tumor characteristics and metastatic potential. Immunohistochemical technique was used to identify the cellular location and distribution of the enzymes in the specific cells of gastric tumors. In gastric cancer tissue, the expression of inducible enzymes, iNOS and COX-2, increased significantly with increasing tumor stage (P = 0.015, P = 0.001, respectively), size (P = 0.025, P = 0.001, respectively) and the presence of metastases (P = 0.002, P = 0.015, respectively). The expression of constitutive enzymes, ecNOS and COX-1, followed the opposite pattern. COX-1 was significantly reduced in advanced gastric tumors (P = 0.007) and tumors larger than 5 cm (P = 0.007). Reduced expression of ecNOS was also observed in advanced gastric tumors; however, this did not reach statistical significance. 53% of gastric tumors showed accumulation of p53. This was significantly higher in advanced tumors (P = 0.004), larger than 5 cm (P = 0.015) with metastases (P < 0.001). Gastric tumors positive for accumulation of p53 had significantly stronger expression of iNOS (P = 0.018) and COX-2 (P = 0.01) enzymes than tumors negative for this nucleophosphoprotein. We conclude, that tumor-associated nitric oxide production, as well as COX-2 overexpression, may promote gastric cancer progression by providing a selective growth advantage to tumor cells with non-functioning p53. © 2001 Elsevier Science Ireland Ltd. All rights reserved.
Source Title: Cancer Letters
ISSN: 03043835
DOI: 10.1016/S0304-3835(01)00645-0
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on May 25, 2022


checked on May 25, 2022

Page view(s)

checked on May 26, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.